Fig. 2From: Nivolumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced gastric, gastroesophageal junction, and esophageal adenocarcinoma: a cost-effectiveness analysisModelled survival curves for chemotherapy plus nivolumab and chemotherapy alone groupPFS: progression-free survival; OS: overall survival; CPS: combined positive scoreBack to article page